Regeneron Pharma (REGN) Guides FY12 Eylea Sales
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $834.04 +0.90%
Financial Fact:
Investment income: 3.3M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Investment income: 3.3M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Regeneron Pharma (Nasdaq: REGN) sees FY12 Eylea sales in the US of $250-$300 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
- Regeneron Announces Investor Conference Presentations
Create E-mail Alert Related Categories
GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
